Self-inactivating alpharetroviral vectors with a split-packaging design

Journal of Virology

Volumn 84, Issue 13, 2010, Pages 6626-6635

  Suerth, Julia D ^a   Maetzig, Tobias ^a   Galla, Melanie ^a   Baum, Christopher ^a   Schambach, Axel ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHARETROVIRAL VECTOR; RETROVIRUS VECTOR; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ANIMAL CELL; ARTICLE; CODON; DNA MODIFICATION; DNA PACKAGING; EXPRESSION VECTOR; HUMAN; HUMAN CELL; IMMUNOGENICITY; LONG TERMINAL REPEAT; MAMMAL CELL; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETROVIRUS; TRANSGENE; VIRUS GENOME; VIRUS REPLICATION; VIRUS TRANSCRIPTION;

ALPHARETROVIRUS; ANIMALS; CELL LINE; CELLS, CULTURED; GENE EXPRESSION; GENE THERAPY; GENETIC VECTORS; HUMANS; MICE; PROMOTER REGIONS, GENETIC; RNA, VIRAL; TERMINAL REPEAT SEQUENCES; TRANSGENES; VIRUS ASSEMBLY;

ALPHARETROVIRUS; MAMMALIA; MURINAE; ROUS SARCOMA VIRUS;

EID: 77953311295     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.00182-10     Document Type: Article

References (46)

1. Baum, C., S. Hegewisch-Becker, H. G. Eckert, C. Stocking, and W. Ostertag. 1995. Novel retroviral vectors for efficient expression of the multidrug-resistance (mdr-1) gene in early hemopoietic cells. J. Virol. 69:7541-7547.
2. Beyer, W. R., M. Westphal, W. Ostertag, and D. von Laer. 2002. Oncoretrovirus and lentivirus vectors pseudotyped with lymphocytic choriomeningitis virus glycoprotein: generation, concentration, and broad host range. J. Virol. 76:1488-1495.
3. Bokhoven, M., S. L. Stephen, S. Knight, E. F. Gevers, I. C. Robinson, Y. Takeuchi, and M. K. Collins. 2009. Insertional gene activation by lentiviral and gammaretroviral vectors. J. Virol. 83:283-294.
4. Donahue, R. E., S. W. Kessler, D. Bodine, K. McDonagh, C. Dunbar, S. Goodman, B. Agricola, E. Byrne, M. Raffeld, and R. Moen. 1992. Helper virus induced T cell lymphoma in nonhuman primates after retroviral mediated gene transfer. J. Exp. Med. 176:1125-1135.
5. Dull, T., R. Zufferey, M. Kelly, R. J. Mandel, M. Nguyen, D. Trono, and L. Naldini. 1998. A third-generation lentivirus vector with a conditional packaging system. J. Virol. 72:8463-8471. (Pubitemid 28471781)
6. Fehse, B., O. S. Kustikova, M. Bubenheim, and C. Baum. 2004. Pois(s)on - it's a question of dose .. . Gene Ther. 11:879-881.
7. Graf, M., A. Bojak, L. Deml, K. Bieler, H. Wolf, and R. Wagner. 2000. Concerted action of multiple cis-acting sequences is required for Rev. dependence of late human immunodeficiency virus type 1 gene expression. J. Virol. 74:10822-10826.
8. Hacein-Bey-Abina, S., A. Garrigue, G. P. Wang, J. Soulier, A. Lim, E. Morillon, E. Clappier, L. Caccavelli, E. Delabesse, K. Beldjord, V. Asnafi, E. MacIntyre, L. Dal Cortivo, I. Radford, N. Brousse, F. Sigaux, D. Moshous, J. Hauer, A. Borkhardt, B. H. Belohradsky, U. Wintergerst, M. C. Velez, L. Leiva, R. Sorensen, N. Wulffraat, S. Blanche, F. D. Bushman, A. Fischer, and M. Cavazzana-Calvo. 2008. Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J. Clin. Invest. 118:3132-3142.
9. Howe, S. J., M. R. Mansour, K. Schwarzwaelder, C. Bartholomae, M. Hubank, H. Kempski, M. H. Brugman, K. Pike-Overzet, S. J. Chatters, D. de Ridder, K. C. Gilmour, S. Adams, S. I. Thornhill, K. L. Parsley, F. J. Staal, R. E. Gale, D. C. Linch, J. Bayford, L. Brown, M. Quaye, C. Kinnon, P. Ancliff, D. K. Webb, M. Schmidt, C. von Kalle, H. B. Gaspar, and A. J. Thrasher. 2008. Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients. J. Clin. Invest. 118:3143-3150.
10. Hu, J., A. Ferris, A. Larochelle, A. E. Krouse, M. E. Metzger, R. E. Donahue, S. H. Hughes, and C. E. Dunbar. 2007. Transduction of rhesus macaque hematopoietic stem and progenitor cells with avian sarcoma and leukosis virus vectors. Hum. Gene Ther. 18:691-700.
11. Hu, J., G. Renaud, T. J. Gomes, A. Ferris, P. C. Hendrie, R. E. Donahue, S. H. Hughes, T. G. Wolfsberg, D. W. Russell, and C. E. Dunbar. 2008. Reduced genotoxicity of avian sarcoma leukosis virus vectors in rhesus longterm repopulating cells compared to standard murine retrovirus vectors. Mol. Ther. 16:1617-1623.
12. Hughes, S., and E. Kosik. 1984. Mutagenesis of the region between env and src of the SR-A strain of Rous sarcoma virus for the purpose of constructing helper-independent vectors. Virology 136:89-99. (Pubitemid 14089590)
13. Hughes, S. H. 2004. The RCAS vector system. Folia Biol. (Praha) 50:107-119.
14. Hughes, S. H., J. J. Greenhouse, C. J. Petropoulos, and P. Sutrave. 1987. Adaptor plasmids simplify the insertion of foreign DNA into helper-independent retroviral vectors. J. Virol. 61:3004-3012.
15. Jacks, T., H. D. Madhani, F. R. Masiarz, and H. E. Varmus. 1988. Signals for ribosomal frameshifting in the Rous sarcoma virus gag-pol region. Cell 55:447-458.
16. Kustikova, O. S., A. Wahlers, K. Kuehlcke, B. Staehle, A. R. Zander, C. Baum, and B. Fehse. 2003. Dose finding with retroviral vectors: correlation of retroviral vector copy numbers in single cells with gene transfer efficiency in a cell population. Blood 102:3934-3937.
17. Loftus, S. K., D. M. Larson, D. Watkins-Chow, D. M. Church, and W. J. Pavan. 2001. Generation of RCAS vectors useful for functional genomic analyses. DNA Res. 8:221-226.
18. Logan, A. C., D. L. Haas, T. Kafri, and D. B. Kohn. 2004. Integrated self-inactivating lentiviral vectors produce full-length genomic transcripts competent for encapsidation and integration. J. Virol. 78:8421-8436.
19. Maetzig, T., M. Galla, M. Brugman, R. Loew, C. Baum, and A. Schambach. 2010. Mechanisms controlling titer and expression of bidirectional lentiviral and gammaretroviral vectors. Gene Ther. 17:400-411.
20. Marczinke, B., R. Fisher, M. Vidakovic, A. J. Bloys, and I. Brierley. 1998. Secondary structure and mutational analysis of the ribosomal frameshift signal of Rous sarcoma virus. J. Mol. Biol. 284:205-225.
21. Mitchell, R. S., B. F. Beitzel, A. R. Schroder, P. Shinn, H. Chen, C. C. Berry, J. R. Ecker, and F. D. Bushman. 2004. Retroviral DNA integration: ASLV, HIV, and MLV show distinct target site preferences. PLoS Biol. 2:E234.
22. Modlich, U., J. Bohne, M. Schmidt, C. von Kalle, S. Knoss, A. Schambach, and C. Baum. 2006. Cell-culture assays reveal the importance of retroviral vector design for insertional genotoxicity. Blood 108:2545-2553.
23. Modlich, U., S. Navarro, D. Zychlinski, T. Maetzig, S. Knoess, M. H. Brugman, A. Schambach, S. Charrier, A. Galy, A. J. Thrasher, J. Bueren, and C. Baum. 2009. Insertional transformation of hematopoietic cells by self-inactivating lentiviral and gammaretroviral vectors. Mol. Ther. 17:1919-1928.
24. Montini, E., D. Cesana, M. Schmidt, F. Sanvito, C. C. Bartholomae, M. Ranzani, F. Benedicenti, L. S. Sergi, A. Ambrosi, M. Ponzoni, C. Doglioni, C. Di Serio, C. von Kalle, and L. Naldini. 2009. The genotoxic potential of retroviral vectors is strongly modulated by vector design and integration site selection in a mouse model of HSC gene therapy. J. Clin. Invest. 119:964-975.
25. Morita, S., T. Kojima, and T. Kitamura. 2000. Plat-E: an efficient and stable system for transient packaging of retroviruses. Gene Ther. 7:1063-1070.
26. Ogert, R. A., L. H. Lee, and K. L. Beemon. 1996. Avian retroviral RNA element promotes unspliced RNA accumulation in the cytoplasm. J. Virol. 70:3834-3843.
27. Pfaffl, M. W. 2001. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 29:e45.
28. Rahman, L., V. Bliskovski, F. J. Kaye, and M. Zajac-Kaye. 2004. Evolutionary conservation of a 2-kb intronic sequence flanking a tissue-specific alternative exon in the PTBP2 gene. Genomics 83:76-84.
29. + cells derived from human and nonhuman primates. Blood 100:823-832.
30. Schambach, A., J. Bohne, C. Baum, F. G. Hermann, L. Egerer, D. von Laer, and T. Giroglou. 2006. Woodchuck hepatitis virus post-transcriptional regulatory element deleted from X protein and promoter sequences enhances retroviral vector titer and expression. Gene Ther. 13:641-645.
31. Schambach, A., J. Bohne, S. Chandra, E. Will, G. P. Margison, D. A. Williams, and C. Baum. 2006. Equal potency of gammaretroviral and lentiviral SIN vectors for expression of O6-methylguanine-DNA methyltransferase in hematopoietic cells. Mol. Ther. 13:391-400.
32. Schambach, A., M. Galla, U. Modlich, E. Will, S. Chandra, L. Reeves, M. Colbert, D. A. Williams, C. von Kalle, and C. Baum. 2006. Lentiviral vectors pseudotyped with murine ecotropic envelope: increased biosafety and convenience in preclinical research. Exp. Hematol. 34:588-592.
33. Schambach, A., D. Mueller, M. Galla, M. M. Verstegen, G. Wagemaker, R. Loew, C. Baum, and J. Bohne. 2006. Overcoming promoter competition in packaging cells improves production of self-inactivating retroviral vectors. Gene Ther. 13:1524-1533.
34. Schröder, A. R., P. Shinn, H. Chen, C. Berry, J. R. Ecker, and F. Bushman. 2002. HIV-1 integration in the human genome favors active genes and local hotspots. Cell 110:521-529.
35. Soneoka, Y., P. M. Cannon, E. E. Ramsdale, J. C. Griffiths, G. Romano, S. M. Kingsman, and A. J. Kingsman. 1995. A transient three-plasmid expression system for the production of high titer retroviral vectors. Nucleic Acids Res. 23:628-633.
36. Sonstegard, T. S., and P. B. Hackett. 1996. Autogenous regulation of RNA translation and packaging by Rous sarcoma virus Pr76gag. J. Virol. 70:6642-6652.
37. Sorge, J., W. Ricci, and S. H. Hughes. 1983. cis-acting RNA packaging locus in the 115-nucleotide direct repeat of Rous sarcoma virus. J. Virol. 48:667-675.
38. Thornhill, S. I., A. Schambach, S. J. Howe, M. Ulaganathan, E. Grassman, D. Williams, B. Schiedlmeier, N. J. Sebire, H. B. Gaspar, C. Kinnon, C. Baum, and A. J. Thrasher. 2008. Self-inactivating gammaretroviral vectors for gene therapy of X-linked severe combined immunodeficiency. Mol. Ther. 16:590-598.
39. Trobridge, G. D. 2009. Foamy virus vectors for gene transfer. Expert Opin. Biol. Ther. 9:1427-1436.
40. Vogt, V. M., D. A. Bruckenstein, and A. P. Bell. 1982. Avian sarcoma virus gag precursor polypeptide is not processed in mammalian cells. J. Virol. 44:725-730.
41. Wahlers, A., M. Schwieger, Z. Li, D. Meier-Tackmann, C. Lindemann, H. G. Eckert, D. von Laer, and C. Baum. 2001. Influence of multiplicity of infection and protein stability on retroviral vector-mediated gene expression in hematopoietic cells. Gene Ther. 8:477-486.
42. Weber, F., and W. Schaffner. 1985. Enhancer activity correlates with the oncogenic potential of avian retroviruses. EMBO J. 4:949-956.
43. Wu, X., Y. Li, B. Crise, and S. M. Burgess. 2003. Transcription start regions in the human genome are favored targets for MLV integration. Science 300:1749-1751.
44. Yee, J. K., T. Friedmann, and J. C. Burns. 1994. Generation of high-titer pseudotyped retroviral vectors with very broad host range. Methods Cell Biol. 43(Pt. A):99-112.
45. Zufferey, R., T. Dull, R. J. Mandel, A. Bukovsky, D. Quiroz, L. Naldini, and D. Trono. 1998. Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery. J. Virol. 72:9873-9880. (Pubitemid 28520853)
46. Zychlinski, D., A. Schambach, U. Modlich, T. Maetzig, J. Meyer, E. Grassman, A. Mishra, and C. Baum. 2008. Physiological promoters reduce the genotoxic risk of integrating gene vectors. Mol. Ther. 16:718-725.